Conference Reports for NATAP

Back

The International Liver Congress™ EASL - European Association for the Study of the Liver June 22-26 2022     Curing HCV with Direct-Acting Antiviral (DAA) Treatment: Adherence and Rapid Onset of HCV-RNA Undetectability after 4 Weeks of Treatment with Sofosbuvir/Velpatasvir - (11/10/22)   EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Infected Patients - (09/03/22)   EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Results of a 28-day Phase 1b Study in NUC-suppressed CHB Patients - (09/03/22)   Phase 1b/2a study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB on nucleos(t)ide analogues - (07/25/22)   Mechanistic pharmacokinetics/pharmacodynamics modelling of the simultaneous effects of bepirovirsen on hepatitis B surface antigen and alanine transaminase changes in chronic hepatitis B patients: Phase 2b analysis to inform Phase 3 decision-making - (07/25/22)   Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection on stable nucleos(t)ide analogue therapy: interim results from the randomised Phase 2b B-Clear study - (07/25/22)   Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study - (07/25/22)   Combination treatment of a PAPD5/7 inhibitor with an antisense oligonucleotide bepirovirsen with concurrent dosing shows additive HBsAg decreases in the AAV-HBV mouse model - (07/25/22)   NAFLD Pipeline - by Rohit Loomba MD - (07/21/22)   Early post liver transplant rescue treatment with sofosbuvir/velpatasvir/voxilaprevir in patients experienced to NS5A-inhibitors - (07/21/22)   Approaches for a Hepatitis C-free city: preliminary results - (07/21/22)   A cluster randomized controlled study of secondary distribution of HCV self-test to support micro-elimination in Karachi, Pakistan - (07/21/22)   From extensive to intensive screening, co-operation model of hepatitis C elimination in out-patients and people who inject drug population in southwest of China - (07/21/22)   Improved recurrence-free survival rates in patients with HCV-related hepatocellular carcinoma and sustained virological response to direct-acting antivirals - (07/21/22)   Hepatocellular carcinoma risks of liver fibrosis changes after viral eradication in chronic hepatitis C patients - (07/21/22)   Hepatocellular carcinoma risks of liver fibrosis changes after viral eradication in chronic hepatitis C patients - (07/21/22)   Distinct hepatocellular carcinoma risks in treated chronic hepatitis C patients with different definitions of advanced chronic liver disease - (07/21/22)   Compassionate use of subcutaneous REP 2139-Mg in cirrhotic HBV / HDV coinfection - (07/21/22)   Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience - (07/21/22)   Improvement of liver-stiffness in HBV/HDV-coinfected patients treated with Bulevirtide - (07/21/22)   Estimations of the global prevalence of occult hepatitis B virus infection (OBI): a systematic review and meta-analysis - (07/21/22)   The Comparison of Tenofovir Alafenamide Fumarate with Tenofovir Disoproxil Fumarate in Preventing Hepatitis B Transmission in Mothers with High Viral Load: A Retrospective Cohort Study - (07/21/22)   Characterizing of hepatitis B virus serum RNA kinetics during TDF plus pegylated interferon alfa-2a with and without nucleic acid polymers - (07/21/22)   Tenofovir Alafenamide for Chinese Pregnant Women with Active Chronic Hepatitis B: A Multicenter Prospective Study - (07/21/22)   Evaluation of the clinical and economic value of sofosbuvir / velpatasvir (SOF / VEL) in patients with chronic hepatitis C in Spain during the last 5 years - (07/14/22)   Safety, Pharmacokinetics, and Antiviral Activity of the Class II Capsid Assembly Modulator ALG-000184 in Subjects with Chronic Hepatitis B and other Aligos studies - (07/14/22)   The Value of Increased HCV Testing and Treatment Strategies in Spain to Achieve Elimination Goals - cost effectiveness analysis - (07/14/22)   The MRI and AST (MAST) Score Is Correlated With Noninvasive and Histologic Markers of Fibrosis in Patients With Advanced Fibrosis Due to NASH - (07/13/22)   Inhibition of Tumor Progression Locus 2 Halts the Progression of Liver Fibrosis in a Stringent Long-term Choline-Deficient High-Fat Diet Rat Model - (07/13/22)   Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022 - (07/11/22)   Concordance of the Xpert hepatitis B viral load test and conventional quantitative PCR in detecting and quantifying viremia using stored plasma and dried blood spot samples in West Africa - (07/11/22)   Reverse Inflammaging: Biological age in HCV after cure - (07/11/22)   Screening for hepatitis C in Denmark- the effect of a mobile outreach intervention - (07/11/22)   Change in fibrosis and clinical progression three years after sustained virological response induced by direct antiviral agents in HIV/HCV subjects - (07/11/22)   Hepatitis C virus reinfection [high] following direct acting antiviral treatment in the prison setting: the SToP-C study - (07/11/22)   Macroeconomic assessment of overall and per-patient healthcare costs of Hepatitis C-infected patients in an integrated health system in the era of direct-acting antiviral therapy - (07/11/22)   Point of care [Cepheid GeneXpert assay] testing for hepatitis C in mental health, prison and drug & alcohol settings - (07/11/22)   HCV Rapid Xpert Point-of-Care Fingerstick Onsite at Addiction Centers in France - (07/11/22)   HCV Homeless Mobile Van with Rapid Xpert Cepheid RNA Test - (07/11/22)   Maximizing the potential of Cepheid, GeneXpert PCR rapid testing for hepatitis C through use of finger prick blood samples collected into EDTA capillary tubes - (07/11/22)   Utilizing Phenotyping Algorithms as Tools for Increasing Linkage to Guideline-Concordant Care in Patients at Risk for Hepatitis B - (07/08/22)   Establishment of a new diagnostic model for significant liver tissue damage in patients with chronic hepatitis B virus infection in the immune tolerance phase - (07/08/22)   HEALTH ECONOMIC OUTCOMES OF A5360 MINMON - (07/08/22)   Hepatitis C Screening Rates in NY by Age Cohort 1945-1965 in a Large, Community Health System (Northwell), Before, During and After the COVID Pandemic - (07/08/22)   Hepatitis delta virus reflex testing in patients with hepatitis B dramatically improves the HDV screening cascade: 10 years of real-world experience from Avicenne University Hospital, France - (07/08/22)   Provider Factors Shaping Hepatitis Delta Screening - (07/08/22)   Validation of an internal hepatitis D virus RNA Quantitative assay: Developing an assay suitable for global clinical application and clinical trials assessment - (07/08/22)   Low carbohydrate high fat diet versus low-fat diet on NAS and HbA1c in people with type 2 diabetes - a randomised controlled trial Results from the REDUCTION trial - (07/08/22)   Towards elimination: A clinical and public health approach to control of hepatitis C and B infection in England - (07/07/22)   Excess mortality risk among hepatitis C patients after being ''cured'' in the interferon-free era: results from three population-based cohorts - (07/07/22)   Associations Between Serum Biomarkers Chitinase-2-Like Protein, Type IV Collagen, and Thrombospondin-2 With Fibrosis Stage and Clinical Outcome in Patients With Primary Sclerosing Cholangitis - (07/07/22)   Higher rates of virological relapse after nucleos(t)ide analogue withdrawal in HBeAg-negative versus positive chronic hepatitis B patients: Results from a global, multi-ethnic cohort of patients with chronic hepatitis B virus infection - (07/06/22)   Comparative risk of hepatocellular carcinoma in patients with chronic hepatitis B receiving tenofovir- or entecavir-based regimens: a meta-analysis using individual patient data - (07/06/22)   Impact of baseline viral load on hepatocellular carcinoma risk during antiviral treatment in non-cirrhotic patients with HBeAg-positive chronic hepatitis B - (07/06/22)   Long-Read Sequencing of HCC Samples Reveals Complete Architecture of HBV Integrations and Chimeric mRNA Isoforms Associated With Oncogenes - (07/06/22)   Decrease in the Burden of Integrated Hepatitis B Virus DNA in Chronic Hepatitis B Patients With Minimally Elevated Alanine Aminotransferase on Tenofovir Disoproxil Fumarate as Revealed by Long-Read DNA Sequencing - (07/06/22)   Evaluation of Renal and Bone Safety at 4 Years in Post-Liver Transplant Patients With Chronic Kidney Disease Receiving Tenofovir Alafenamide for HBV Prophylaxis - (07/06/22)   Real life efficacy, renal and lipid profile data of tenofovir alafenamide in switched chronic hepatitis B patients - (07/06/22)   A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children and Adolescent Patients With Chronic Hepatitis B - (07/06/22)   Strong correlation between HBsAg, ALT and HDV-RNA levels in patients with chronic hepatitis D. Results of Phase 3 D-LIVR study. - (07/06/22)   Clinical features predictive of cirrhosis in a large cohort of patients with chronic hepatitis delta infection - Insights from the D-LIVR trial - (07/06/22)   Peg-Lambda HDV-RNA Kinetics Math Modeling LIMT-1 Study - (07/06/22)   Preclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis B patients - (07/06/22)   Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells - (07/06/22)   Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA+ chronic hepatitis B subjects - (07/06/22)   Pharmacodynamics of durable HBsAg suppression by AB-729 short interfering RNA correlates with pharmacokinetics of RNA-induced silencing complex (RISC) loading within liver - (07/06/22)   Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update - (07/06/22)   Longer treatment duration of monthly VIR-2218 results in deeper and more sustained reductions in hepatitis B surface antigen in participants with chronic hepatitis B infection - (07/06/22)   VIR-2218 Plus VIR-3434 Combination Therapy Reduces Hepatitis B Virus Surface Antigen Levels In Vivo - (07/06/22)   Dose-Dependent Durability of Hepatitis B Surface Antigen Reductions Following Administration of a Single Dose of VIR-3434, a Novel, Neutralizing Vaccinal Monoclonal Antibody - (07/06/22)   Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program - press release - (07/06/22)   Evaluation of the disposition and mass balance recovery of vebicorvir, a first-generation hepatitis B core inhibitor, in rats and humans - (07/06/22)   Evaluation of the drug-drug interaction profile of vebicorvir, a first-generation hepatitis B core inhibitor: findings from Phase 1 and Phase 2a studies - (07/06/22)   Greater sequence diversity during early hepatitis B virus decline on vebicorvir plus entecavir is associated with a lower level of virus rebound following switch to entecavir monotherapy - (07/06/22)   Utility of FIB-4 Thresholds to Identify Patients With At-risk F2-F3 NASH Based on Screening Data From a 2000 Patient Biopsy-Confirmed Cohort of Resmetirom Phase 3 Clinical Trial (MAESTRO-NASH) - (07/06/22)   Biomarkers, Imaging, & Safety in a Well-compensated NASH Cirrhotic Cohort Treated With Resmetirom, a Thyroid Hormone Receptor Beta Agonist, for 52 Weeks - (07/06/22)   Retrospective AI-based Measurement of NASH Histology (AIM-NASH) Analysis of Biopsies From Phase 2 Study of Resmetirom Confirms Significant Treatment-induced Changes in Histologic Features of Nonalcoholic Steatohepatitis - (07/06/22)   A higher Fibrosis-4 (FIB-4) score is associated with higher healthcare costs and hospitalizations in patients with nonalcoholic steatohepatitis (NASH) - (07/06/22)   Rising Clinical and Economic Burden Among Hepatitis D Patients Who Attended Spanish Hospitals - (07/02/22)   Impact of Patient-Related Factors on the Pharmacokinetics of Bulevirtide - (07/02/22)   Polymorphic Analysis of Bulevirtide Sequence in preS1 of Large HBsAg Across HBV Genotypes A-H - (07/02/22)   Integrated Safety Analysis of 24-Week Data From Three Phase 2 and One Phase 3 Clinical Trial of Bulevirtide Monotherapy Given at 2- or 10-mg Dose Level for Treatment of Chronic Hepatitis Delta - (07/02/22)   Peginterferon Lambda (IFN-λ) combined with Lonafarnib diminished triphasic HDV kinetic pattern seen under IFN-λ monotherapy: The LIFT-1 Study - (07/02/22)   Mathematical modeling of HDV RNA kinetics suggests high peginterferon lambda efficacy in blocking viral production: Insights from the LIMT-1 study - (07/02/22)   Estimating the Prevalence of Hepatitis Delta Infection among Foreign-Born Adults with Chronic Hepatitis B in the United States - (07/02/22)   Hepatitis Delta Management in the United States: An Analysis Of All-Payer Claims Database - (07/02/22)   Healthcare Resource Utilization and Costs of Hepatitis Delta in the United States: An Analysis of All-Payer Claims Database - (07/02/22)   HCV cure in people with psychiatric disorders is associated with a global reduction in hospitalizations - (07/02/22)   Identifying risk factors associated with hepatitis C virus infection in participants in the National Health and Nutrition Examination Survey using Super Learner - (07/02/22)   Multicenter prospective study for the use of shortened pre-emptive therapy with Glecaprevir/Pibrentasvir (G/P) and Ezetimibe in hepatitis C (HCV) seronegative non-liver solid organ transplant recipients of HCV viremic grafts - (07/02/22)   Micro-eliminating Hepatitis C in a network of 48 English Prisons through an industry, prison healthcare and patient organisation partnership - (07/02/22)   The disease burden of hepatitis B and hepatitis C from 2015 to 2030: the long and winding road New HBV and HCV Projected to Decline Thru 2030, But New HCC Cases Will Rise for both HCV & HBV, HBV liver related deaths expected to increase by 30% - Mark Mascolini - (07/01/22)   GLE/PIB + SOF Effective After Failure of Prior DAAs, Including GLE/PIB - Mark Mascolini - (07/01/22)   Simvastatin May Boost Beta Blocker Carvedilol Impact on Portal Hypertension, Modulates Systemic Inflammation - Mark Mascolini - (07/01/22)   More Alcohol Public Health Policies Tied to Fewer Alcohol, Cirrhosis, CVD Deaths, HCC - Mark Mascolini - (07/01/22)   Waist-to-Hip Ratio Predicts Liver Disease Better Than Body Mass Index - Mark Mascolini - (07/01/22)   Lifestyle factors and population attributable risk of hepatocellular carcinoma in lean vs non-lean populations - More Coffee Tied to Lower Liver Cancer Risk in US Group - Mark Mascolini - (07/01/22)   One Third With HDV Respond to Bulevirtide Monotherapy Through 24 Weeks (2 & 10 mg) - Integrated Analysis from 2 Phase 2 & 1 Phase 3 Trials - Mark Mascolini - (07/01/22)   Risk of Dangerous Interactions When Giving DAAs With Other Meds - Mark Mascolini - (07/01/22)   DAAs Cut Cardio Event Rate in HCV+ But Boost Arrhythmia Risk - Mark Mascolini - (07/01/22)   All-Cause Mortality 3 to 15 Times Higher After HCV SVR Than in General Population - Mark Mascolini - (07/01/22)   One Third With HDV Respond to Bulevirtide Monotherapy Through 24 Weeks (2 & 10 mg) - Integrated Analysis from 2 Phase 2 & 1 Phase 3 Trials - Mark Mascolini - (07/01/22)   Validation of the new 2021 EASL algorithm for the non-invasive diagnosis of advanced liver fibrosis in non-alcoholic fatty liver disease EASL Algorithm Accurate for Advanced Fibrosis in NAFLD - Mark Mascolini (07/01/22)   Leronlimab, mAb to CCR5, Trims Liver Fat in 14-Week Trial of NASH Patients - Mark Mascolini - (07/01/22)   FibroScan Score Predicts Liver Outcomes in HIV+ With NAFLD Risk - Mark Mascolini - (07/01/22)   Semaglutide 2.4 mg once weekly improved liver and metabolic parameters, and was well tolerated, in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial - (07/01/22)   Health-related quality of life is impaired in people living with HIV and hepatic steatosis - (06/30/22)   The 'Viennese epidemic' of acute HCV in the era of direct - acting antivirals - (06/30/22)   Randomized controlled trial of home-based hepatitis C self-testing for key populations in Malaysia - (06/30/22)   - (06/30/22)   Impact of Resmetirom-Mediated Reductions in Liver Volume & Steatosis Compared With Placebo on the Quantification of Fibrosis Using Second Harmonic Generation in a Serial Liver Biopsy Study - (06/30/22)   ABI-4334, a novel inhibitor of hepatitis B virus core protein, promotes formation of empty capsids and prevents cccDNA formation by disruption of incoming capsids - (06/30/22)   Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL's International Liver Congress™ 2022 - (06/30/22)   Long-term HBsAg suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects - (06/30/22)   Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB) - (06/30/22)   Viral nucleic acids suppression activity of RO7049389 plus NUC with/without Peg-IFN in virologically-suppressed and treatment-naïve chronic hepatitis B patients: 48-week treatment and post treatment follow up - (06/30/22)   Continued suppression of viral markers observed following discontinuation of nucleos(t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729 - (06/30/22)   Hepatitis B virus antigen reduction effect of RO7049389 plus NUC with/without Peg-IFN in chronic hepatitis B patients - (06/27/22)   Evidence of Past Hepatitis C and D Co-Infection in Hepatitis B Seronegative Individuals - (06/27/22)   EASL 2022 HCV Wrap-Up: Very Far from WHO Goals-HCC & Deaths Increasing-Infections Not Improving Much - (06/27/22)   EASL 2022 HBV, HDV Wrap-Up - (06/27/22)   Effects of the siRNA JNJ-3989 and/or the Capsid Assembly Modulator JNJ-6379 on Viral Markers of Chronic Hepatitis B: Results From the REEF-1 Study - (06/27/22)   Peginterferon Lambda (IFN-λ) combined with Lonafarnib diminished triphasic HDV kinetic pattern seen under IFN-λ monotherapy: The LIFT-1 Study - (06/27/22)   Glecaprevir/pibrentasvir & sofosbuvir for 16 weeks without ribavirin is safe and highly effective retreatment for patients who have failed an NS5A inhibitor containing antiviral regimen - (06/27/22)   Primary Data Analyses of MAESTRO-NAFLD-1:a 52-week Double-blind, Placebo-controlled Phase 3 Clinical Trial of Resmetirom in Patients With NAFLD - (06/27/22)   Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL's International Liver Congress™ - (06/27/22)   The disease burden of hepatitis B and C from 2015- 2030: The long and winding road towards elimination - (06/27/22)   The Global Burden of Liver Cancer (LC) and Chronic Liver Diseases (CLD) is Driven by Nonalcoholic Steatohepatitis (NASH) and Alcohol Liver Disease (ALD) - (06/27/22)   Real life study of bulevirtide in chronic hepatitis Delta: preliminary results of the ANRS I MIE HD EP01 HDV prospective cohort - (06/26/22)   Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 2a Study; ATI-1428 and ATI-1645 Exhibit Potent Antiviral Activity in a Nonclinical Study - (06/26/22)   Improving the pharmacokinetic profile of the hepatitis B virus core inhibitor ABI-H3733 following oral administration: results from new formulation activities - (06/26/22)   Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment-naïve patients with HBeAg positive chronic hepatitis B - (06/26/22)   Sustained 12 Week Off Treatment Antiviral Efficacy of ATI-2173, a Novel Active Site Polymerase Inhibitor Nucleotide (ASPIN), Combined With Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients, a Phase 2a Clinical Trial - (06/26/22)   Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection: interim results from the randomised Phase 2b B-Clear study - (06/26/22)   Therapeutic Vaccine JNJ-0535 Induces a Strong HBV-specific T-cell Response in Healthy Adults and a Modest Response in Chronic HBV-infected Patients VOX/VEL/SOF Effective Rescue After DAA Failure-With Limits - (06/26/22)   Voxilaprevir/Velpatasvir/Sofosbuvir Efficacy in hepatitis C patients previously treated with direct-acting antiviral agents (DAA) VOX/VEL/SOF Effective Rescue After DAA Failure-With Limits - Mark Mascolini (06/25/22)   Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA) - (06/25/22)   Efficacy and Safety of Finite 48-week Treatment With the siRNA JNJ-3989 and the Capsid Assembly Modulator JNJ-6379 in HBeAg Negative Virologically Suppressed Chronic Hepatitis B Patients: Results from the REEF-2 Study - (06/25/22)   Association between Hepatitis Delta Virus with Liver Morbidity and Mortality: A Systematic Literature Review and Meta-Analysis - (06/25/22)   Evaluating Hepatitis Delta Virus Disease Prevalence and Patient Characteristics Among Adults in the United States: An Analysis of All-Payer Claims Database - (06/25/22)   Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide -Results of a "real world study" - (06/25/22)   No Detectable Resistance to Bulevirtide in Participants With Chronic Hepatitis D Through 24 Weeks of Treatment - (06/25/22)   Full-length genome characterization of inherently resistant african HCV genotype 1, subtype 1l in patients failing DAA-based therapy - (06/24/22)   Impact of Direct-Acting Antiviral Treatment for Hepatitis C on Cardiovascular Diseases and Extrahepatic Cancers - (06/24/22)   Fibroscan-AST (FAST) score predicts liver-related outcomes in 1683 HIV-infected patients at risk for NAFLD - (06/24/22)   Efficacy and Safety of Bulevirtide Monotherapy Given at 2 mg or 10 mg Dose Level Once Daily for Treatment of Chronic Hepatitis Delta: Week 48 Primary Endpoint Results From a Phase 3 Randomized, Multicenter, Parallel Design Study - (06/24/22)   Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta - Mark Mascolini (06/24/22)   Don't Delay Rescue 2nd Line HCV Therapy "Dismal Prognosis" After First DAA Failure in People With Pretreatment Cirrhosis - Mark Mascolini (06/24/22)   Don't Delay DAAs in People Taking Antiepileptics, Elite Experts Advise - Mark Mascolini (06/24/22)   Clinical impact of drug interaction in the use of antipsychotics by HCV patients treated with pangenotypic direct-acting antivirals - (06/24/22)   Infrequent hepatitis C genotypes/subtypes in patients treated with DAA-based regimens: successes and failures - (06/24/22)   Early post liver transplant rescue treatment with sofosbuvir/velpatasvir/voxilaprevir in patients experienced to NS5A-inhibitors - (06/24/22)   Polypharmacy and prevalence of multiple drug-drug interactions in hepatitis C patients treated with pangenotypic direct-acting antivirals: an analysis from three European countries - (06/24/22)   Use of comedication in patients with hepatitis C and addiction or drug abusetreated with direct-acting antivirals: implication in drug-drug interactions - (06/24/22)   Evaluation of Global Progress towards HBV and HCV elimination - off track - (06/23/22)   Healthcare Resource Utilization in Treatment-Naïve Patients With Compensated Cirrhosis Receiving 8-Weeks' Glecaprevir/Pibrentasvir Stratified by Drug Use and Socioeconomic Status: A Retrospective Chart Review - (06/23/22)   Eight Weeks of Glecaprevir/Pibrentasvir is Well Tolerated and Yields High Sustained Virological Response in HCV-Infected Treatment-Naïve Patients With Compensated Cirrhosis: Final Results From the CREST Study - (06/23/22)   Reported Safety of HCV Direct-Acting Antivirals With Opioids: 2017 to 2021 - (06/23/22)   Use of Glecaprevir/Pibrentasvir (G/P) for the treatment of HCV infection among fentanyl users: an interim analysis of the GRAND PLAN study - High Cure Rates - (06/23/22)   Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment naïve patients with compensated cirrhosis: real-world experience from Taiwan HCV Registry - (06/23/22)   Treating HCV in Dual Diagnosis Acute Psychiatric Inpatients with Substance Use Disorder - (06/23/22)   Efficacy and safety of direct-acting antivirals in children and adolescents with chronic hepatitis C virus infection: a systematic review and meta-analysis - (06/23/22)   Association of sustained virologic response with measures of direct-acting antiviral adherence in patients with Hepatitis C: Data from the ASCEND and ANCHOR investigations - (06/23/22)   Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset - in order to achieve HCV Elimination with Focused Treatment Approaches - (06/23/22)   Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: Multicenter, single arm, phase 2 Study The HepNet acute HCV V study - (06/23/22)   Sofosbuvir/Velpatasvir (S/V) for the treatment of HCV infection among vulnerable inner-city residents: extending the results of clinical trial - (06/23/22)   Long-term follow-up of HCV resistance-associated substitutions after DAA treatment failure - (06/23/22)   Real-life effectiveness and safety of sofosbuvir/velpatasvir in difficult to treat hepatitis C patients - (06/23/22)   Establishing a Protocol for Management and DAA Treatment of HCV During Pregnancy: adherence to a co-located care protocol - (06/23/22)   National HCV Paediatric Multidisciplinary Operational Delivery Network (pMDT ODN) - (06/23/22)   From extensive to intensive screening, co-operation model of hepatitis C elimination in out-patients and people who inject drug population in southwest of China - (06/23/22)   REAL-WORLD VALUE AND INNOVATION OF DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF CHRONIC HEPATITIS C AT Kaiser PERMANENTE SOUTHERN CALIFORNIA - (06/23/22)